Highly Diverse Hepatitis C Strains Detected in Sub-Saharan Africa Have Unknown Susceptibility to Direct-Acting Antiviral Treatments

Simple item page
dc.contributor.authorDavis, Chris
dc.contributor.authorMgomella, George S.
dc.contributor.authorFilipe, Ana da Silva
dc.contributor.authorFrost, Eric H.
dc.contributor.authorKaleebu, Pontiano
dc.contributor.authorsiki, Gershim A
dc.contributor.authorMcLauchlan, John
dc.contributor.authorOcama, Ponsiano
dc.contributor.authorPomila, Cristina
dc.contributor.authorPybus, Oliver G.
dc.contributor.authorWekesa, Clara
dc.contributor.authorYoung, Elizabeth H.
dc.date.accessioned2022-04-30T20:45:47Z
dc.date.available2022-04-30T20:45:47Z
dc.date.issued2019
dc.description.abstractThe global plan to eradicate hepatitis C virus (HCV) led by the World Health Organization outlines the use of highly effective direct-acting antiviral drugs (DAAs) to achieve elimination by 2030. Identifying individuals with active disease and investigation of the breadth of diversity of the virus in sub-Saharan Africa (SSA) is essential as genotypes in this region (where very few clinical trials have been carried out) are distinct from those found in other parts of the world. We undertook a population-based, nested case-control study in Uganda and obtained additional samples from the Democratic Republic of Congo (DRC) to estimate the prevalence of HCV, assess strategies for disease detection using serological and molecular techniques, and characterize genetic diversity of the virus. Using next-generation and Sanger sequencing, we aimed to identify strains circulating in East and Central Africa. A total of 7,751 Ugandan patients were initially screened for HCV, and 20 PCR-positive samples were obtained for sequencing. Serological assays were found to vary significantly in specificity for HCV. HCV strains detected in Uganda included genotype (g) 4k, g4p, g4q, and g4s and a newly identified unassigned g7 HCV strain. Two additional unassigned g7 strains were identified in patients originating from DRC (one partial and one full open reading frame sequence). These g4 and g7 strains contain nonstructural (ns) protein 3 and 5A polymorphisms associated with resistance to DAAs in other genotypes. Clinical studies are therefore indicated to investigate treatment response in infected patients. Conclusion: Although HCV prevalence and genotypes have been well characterized in patients in well-resourced countries, clinical trials are urgently required in SSA, where highly diverse g4 and g7 strains circulate.en_US
dc.identifier.citationDavis, C., Mgomella, G. S., da Silva Filipe, A., Frost, E. H., Giroux, G., Hughes, J., ... & Thomson, E. C. (2019). Highly diverse hepatitis C strains detected in Sub‐Saharan Africa have unknown susceptibility to direct‐acting antiviral treatments. Hepatology, 69(4), 1426-1441. DOI 10.1002/hep.30342en_US
dc.identifier.other10.1002/hep.30342
dc.identifier.urihttps://nru.uncst.go.ug/handle/123456789/3075
dc.language.isoenen_US
dc.publisherHepatologyen_US
dc.subjectHepatitis C Strainsen_US
dc.subjectSub-Saharan Africaen_US
dc.subjectAntiviral Treatmentsen_US
dc.titleHighly Diverse Hepatitis C Strains Detected in Sub-Saharan Africa Have Unknown Susceptibility to Direct-Acting Antiviral Treatmentsen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Hepatology - 2018 - Davis - Highly Diverse Hepatitis C Strains Detected in Sub‐Saharan Africa Have Unknown Susceptibility.pdf
Size:
754.91 KB
Format:
Adobe Portable Document Format
Description:
Article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medical and Health Sciences